Immune Thrombocytopenia
Immune Thrombocytopenia (ITP) is a rare blood disorder where the immune system mistakenly attacks and destroys platelets, leading to a low platelet count and increased risk of bleeding.
Immune Thrombocytopenia: Pirtobrutinib Study
We are investigating a new medication, pirtobrutinib, for adults with immune thrombocytopenia. The study aims to assess its safety and effectiveness compared to a placebo.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years of age or older?
- Do you have a confirmed diagnosis of primary ITP (a blood disorder)?
- Have you had any blood clots or blockages in your blood vessels in the last 12 months?
- Do you have a history of significant cardiovascular disease (heart problems)?
- Have you ever been diagnosed with a blood-related cancer?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Odense University Hospital
Haematology
Odense, Denmark
Centre Hospitalier Universitaire De Bordeaux
Médecine Interne – Maladies Infectieuses
Canéjan, France
Assistance Publique Hopitaux De Paris
Service de Médecine Interne
Créteil, France
Sponsor: Eli Lilly & Co.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.